Clinical Trial Update: Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bevacizumab for symptomatic vestibular schwannoma in patients with neurofibromatosis type 2 has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type 2
• Vestibular Schwannoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Vestibular Schwannoma, Neurofibromatosis Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2017-08-17